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Abstract
Background: Although sorafenib is accepted as the standard of care in advanced hepatocellular carcinoma (HCC),
its therapeutic benefit is marginal. Here, we aimed to compare the efficacy and safety of sorafenib monotherapy (S-
M) and sorafenib-based loco-regional treatments (S-LRTs) in advanced HCC.
Methods: From 2007 to 2012, 290 patients with advanced HCC (Barcelona Clinic Liver Cancer stage C) with S-M (n
= 226) or S-LRTs (n = 64) were reviewed retrospectively. Survival outcomes and treatment-related toxicities between
two groups were analyzed.
Results: Variables related to tumor burden and liver function were similar between the groups (all P > 0.05). Within
the entire population, the S-LRTs group had both longer median overall survival (OS) (8.5 vs 5.5 months, P = 0.001)
and progression-free survival (PFS) (5.3 vs 3.0 months, P = 0.002) than the S-M group. Furthermore, the S-LRTs
group had longer Os than the S-M group in a subgroup with neither extrahepatic spread (EHS) nor regional nodal
involvement (RNI) (18.0 vs 7.8 months, P = 0.019) and in a subgroup with EHS and/or RNI (8.3 vs 4.8 months, P =
0.028). In addition, the S-LRTs group had longer PFS than the S-M group in the subgroup with neither EHS nor RNI
(9.6 vs 3.2 months, P = 0.027).
Treatment: Related toxicity was similar between two groups.
Conclusion: Combined use of sorafenib and LRTs may provide better treatment outcomes without significantly
increasing treatment-related toxicities, even in patients with EHS and/or RNI. Therefore, addition of active LRTs
might be considered, if feasible.
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Introduction
Hepatocellular carcinoma (HCC) is currently ranked as the
ﬁfth most common cancer and the third leading cause of
cancer death worldwide [1]. Surgical resection or local ablative
treatments such as radiofrequency ablation and percutaneous
ethanol injection achieve the best outcomes, with a 5-year
survival rate of 60–70% in patients treated during early stages.
Unfortunately, this is not feasible for the majority of patients
with HCC, because they present with advanced disease,
consisting of extensive tumor burden with portal vein
thrombosis, intra/extra tumor spread, or poor liver function
[2,3].
To date, several palliative therapeutic options have been
used to treat advanced HCC. These include trans-arterial
chemoembolization (TACE), hepatic artery infusional
chemotherapy (HAIC), external/internal irradiation, and
molecular targeted agents [4-6]. Of these, sorafenib, a small-
molecule multi-targeted tyrosine kinase inhibitor, is the ﬁrst
targeted agent approved for the systemic treatment of
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advanced HCC. Sorafenib inhibits vascular endothelial growth
factor receptor, platelet-derived growth factor receptor, B-Raf,
Fms-related tyrosine kinase, and c-kit at nanomolar
concentrations [7,8]. Further, sorafenib demonstrates survival
benefits when compared to the best supportive care [5,6] and
has thus become the principal therapy for patients with
advanced HCC or Barcelona Clinic Liver Cancer (BCLC) stage
C. It is also currently being used in the control arm of ongoing
clinical trials for new targeted agents [9-12]. Although sorafenib
is the standard treatment for advanced HCC, most patients
treated with sorafenib achieve only stable disease as the best
radiologic response, with a median time to progression of from
2.2 to, at most, 5.5 months. More importantly, its therapeutic
benefit might be substantially attenuated for patients with portal
vein invasion and/or extrahepatic spread. Thus, these patients
will have a much poorer overall survival compared to those
without these two factors [13,14].
Therefore, additional treatment strategies need to be
identified and optimized to improve the therapeutic response.
Furthermore, given that more than two-thirds of patients with
advanced HCC die of liver failure due to intrahepatic tumor
progression rather than from progression of extrahepatic
metastatic disease, loco-regional treatments (LRTs) targeting
the primary tumor should be reappraised from the standpoint of
therapeutic benefit for patients with advanced HCC. Indeed,
before sorafenib treatment was widely accepted for advanced
HCC, several researchers had investigated this issue and
reported some benefits in patients with major vascular invasion
or extrahepatic metastasis where LRTs were used to delay
intra-hepatic tumor progression instead of the best supportive
care [9,10,15,16]. More recently, several studies with small
population have suggested that LRTs when combined with
sorafenib may lead to better clinical outcomes than the
traditional sorafenib-monotherapy (S-M) [17-20].
Here, we aimed to assess the efficacy and safety of the
combined use of sorafenib and LRTs in advanced HCC and
compare these outcomes to those achieved with S-M.
Materials and Methods
Patient Eligibility
Between December 2007 and February 2012 a total of 318
patients with unresectable HCC who were eligible for sorafenib
treatment with or without LRTs were reviewed retrospectively.
Among patients who underwent S-LRT or SM, 28 patients were
excluded according to the following exclusion criteria; short
duration of sorafenib administration (<2 week, n = 21), BCLC
stage A/B (n = 5), Child-Pugh class C (n = 2), and Eastern
Cooperative Oncology Group (ECOG) performance status ≥3
(n = 0). Finally, 290 patients with BCLC C and Child-Pugh class
A or B were analyzed.
This study was performed in accordance with the ethical
guidelines of the 1975 Declaration of Helsinki. Written informed
consent was obtained from each participant or responsible
family member after possible complications of the diagnostic
procedures and anti-cancer treatments had been fully
explained. This study was approved by the independent
institutional review board of Severance Hospital.
Diagnosis of HCC
A diagnosis of HCC was based on histological examination
or clinico-radiologic criteria according to guidelines proposed
by The Korea Liver Cancer Study Group [21] as follows; a
patient is considered positive for HCC if they have one or more
risk factors (hepatitis B or C virus infection, cirrhosis) and one
of the following: 1) serum α-fetoprotein (AFP) ≥ 400 ng/mL and
a positive finding on at least one of three typical imaging
studies [dynamic computed tomography (CT), dynamic
magnetic resonance imaging (MRI), or hepatic angiography], or
2) serum AFP <400 ng/mL and positive findings on at least two
of the three imaging studies. A positive finding for typical HCC
on dynamic CT or MRI was defined as increased arterial
enhancement followed by decreased enhancement compared
with the liver (washout) in the portal or equilibrium phase.
Study Design
Subjects were divided into two groups; 1) patients who were
treated with sorafenib monotherapy (referred to as “S-M
group”), and 2) patients who were treated by other LRTs in
addition to sorafenib (referred to as “S-LRTs group”). Patients
in the S-M group received 400 mg oral sorafenib (Nexavar
Bayer Health Care AG, Leverkusen, Germany) twice daily on a
continuous dosing schedule. In addition to the twice daily 400
mg oral sorafenib, patients in the S-LRTs group also received
LRTs that included intra-arterial chemotherapy (either TACE or
HAIC), external beam radiotherapy, or both to delay
progression of intra-hepatic tumors. The detailed protocols of
LRTs performed at our institution, such as TACE using
doxorubicin, lipiodol, and gelatin sponge particles, HAIC via
implantable port system using 5-fluorouracil and cisplatin, and
three-dimensional conformal external beam radiotherapy were
described previously [22-25]. S-LRTs were performed in
advanced HCC with the tolerable liver function for anti-tumor
therapy in Severance. However, S-M has been applied for
patients who couldn’t afford S-LRTs because national
insurance system didn’t guarantee only one method among
chemotherapy and LRTs.
The time interval between LRTs and initiation of sorafenib is
less than 14 days (median 4 days, range 0–14 days). In both
groups, dose reduction and drug interruption were allowed in
the case of significant drug-related adverse effects or poor
general condition. Sorafenib was also administered until
disease progression, the development of intolerable toxicities,
or patient refusal. However, for patients in the S-LRTs group,
when intrahepatic tumor progression was observed, an
alternative LRTs was allowed to delay intrahepatic disease
progression, according to physician discretion and patient
eligibility.
Evaluation of Treatment Response and Safety Profile
Clinical examination and laboratory assessments were
performed upon the initiation of sorafenib treatment. The
response evaluation was carried out with a dynamic CT scan or
MRI, if appropriate, every 8 weeks. We adopted the modified
Response Evaluation Criteria in Solid Tumors as follows:
complete response (CR), partial response (PR), stable disease
(SD), and progressive disease (PD). Objective response was
Loco-Regional Treatments in Hepatoma
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defined as CR or PR, and disease control as CR, PR, or SD.
Response was analyzed by intention-to-treat analysis. Toxicity
grade was assessed before each treatment cycle using the
National Cancer Institute Common Toxicity Criteria version 3.0
Statistical Analyses
Student’s t test or Mann-Whitney U tests, if appropriate, were
used to compare continuous variables, and Chi-square or
Fisher’s exact tests were used for categorical variables. The
primary endpoint was overall survival (OS), whereas the
secondary endpoints were progression-free survival (PFS) and
treatment-related toxicity. OS was calculated as the time
interval from the initiation date of either sorafenib or LRTs
(provided that LRTs preceded the administration of sorafenib in
the S-LRTs group) until the date of death or final follow-up.
Similarly, PFS was calculated as the time interval from the
initiation date of sorafenib or LRTs until the date of first
progression or death. Survival time was estimated by the
Kaplan-Meier method, and the survival difference between
groups was assessed by the log-rank test. The Cox
proportional hazards model was used for a multivariate
analysis of survival. All variables found significant in the
univariate analysis were included in the multivariate model.
Statistical analyses were performed using SAS version 9.1.3




Table 1 shows the baseline characteristics of the entire
population. The median age was 56.7 years and 243 (83.8%)
patients were male. Most patients (n = 208, 71.7 %) showed
preserved liver function of Child-Pugh class A. The median
tumor size was 4.0 cm. Extrahepatic spreading (EHS) was
identified in 182 (62.8%) patients, whereas regional lymph
nodal involvement (RNI) was noted in 89 (36.0%) patients. The
most common site for EHS was lung (n = 132, 45.5%). The
median AFP and protein induced by vitamin K absence or
antagonist (PIVKA) levels were 110 ng/mL and 112 AU/L,
respectively. In S-LRTs group, sorafenib was combined with
LRTs as follows; TACE (n = 24), HAIC (n = 5), HAIC with
radiotherapy (n = 13), and radiotherapy alone (n = 22). The
proportion of patients with a previous history of treatment for
HCC and non-viral etiology was higher in the S-M group than in
the S-LRTs group (79.6% vs. 67.2%, P = 0.037 and 15.9% vs.
6.2%, P = 0.047, respectively). There was no statistically
significant difference in clinical variables between the two
groups (Table 1).
Treatment Outcomes and Variables Affecting OS
The median OS in the entire population was 6 months [95%
confidence interval (CI) 5.2–6.7]. Subjects in the S-LRTs group
had a significantly longer median OS than those in the S-M
group [8.5 months (95% CI 6.2–10.7 months) vs. 5.5 months
(95% CI 4.7–6.2 months); P = 0.001] (Figure 1). In addition,
Child-Pugh class, tumor size, EHS and/or RNI, AFP level ≥400
ng/mL, PIVKA level ≥1,000 AU/L, and the cumulative dose of
sorafenib (transformed by natural logarithm) significantly
predicted OS in univariate analysis (all P < 0.05) (Table 2).
Subsequent multivariate analysis revealed that combined LRTs
modality with sorafenib remained as the independent predictor
for the better OS [adjusted hazard ratio (HR) 0.5, 95% CI 0.3–
0.8, P = 0.002], together with Child-Pugh class (adjusted HR
1.8, 95% CI 1.2–2.5, P < 0.001), tumor size (adjusted HR 1.5,
95% CI 1.1–2.3, P = 0.030), EHS and/or RNI (adjusted HR 1.7,
95% CI 1.2–2.4, P = 0.001), AFP level (adjusted HR 1.6, 95%
CI 1.1–2.1, P = 0.002), and the cumulative dose of sorafenib
(transformed by natural logarithm) (adjusted HR 0.5, 95% CI
0.4–0.6, P < 0.001 ) (Table 2).
Because lung and/or bone metastasis significantly predicted
OS in univariate analysis (P = 0.033), it was entered into
multivariate analysis, adjusting other significant covariates such
as S-LRTs, Child-Pugh class, tumor size, AFP level ≥400
ng/mL, PIVKA level ≥1,000 AU/L, and the cumulative dose of
sorafenib. However, presence of EHS and/or RNI was not
incorporated into this analysis since presence of EHS and/or
RNI partly included lung and/or bone metastasis. Finally, lung
and/or bone metastasis was also selected as one of the
independent prognostic factor for OS (adjusted HR 1.2, 95% CI
1.1-1.8, P = 0.031) (Table S1).
Treatment Outcomes and Variables Affecting PFS
The median PFS for the entire population was 3.4 months
(95% CI 3.0–3.7). Subjects in the S-LRTs group had a
significantly longer median PFS than those in the S-M group
[5.3 months (95% CI 4.0–6.5 months) vs. 3.0 months (95% CI
2.7–3.2 months); P = 0.002; Figure 1]. In addition, Child-Pugh
class, tumor size, EHS and/or RNI, AFP level ≥400 ng/mL,
PIVKA level ≥1,000 AU/L, and the cumulative dose of sorafenib
(transformed by natural logarithm) significantly predicted PFS
in univariate analysis (all P < 0.05; Table 2). Subsequent
multivariate analysis revealed that combined LRTs modality
with sorafenib remained as the independent predictor for the
better PFS (adjusted HR 0.6, 95% CI 0.4–0.9, P = 0.025),
together with Child-Pugh class (adjusted HR 1.4, 95% CI 1.1–
1.9, P = 0.029), tumor size (adjusted HR 1.6, 95% CI 1.1–2.4,
P = 0.012), EHS and/or RNI (adjusted HR 1.7, 95% CI 1.2–2.4,
P < 0.001 ), AFP level (adjusted HR 1.9, 95% CI 1.4–2.5, P <
0.001), and the cumulative dose of sorafenib (transformed by
natural logarithm) (adjusted HR 0.6, 95% CI 0.5–0.7, P <
0.001) (Table 2).
Because lung and/or bone metastasis significantly predicted
PFS in univariate analysis (P = 0.001), it was entered into
multivariate analysis, adjusting other significant covariates such
as S-LRTs, Child-Pugh class, tumor size, AFP level ≥400
ng/mL, PIVKA level ≥1,000 AU/L, and the cumulative dose of
sorafenib. However, presence of EHS and/or RNI was not
incorporated into this analysis since presence of EHS and/or
RNI partly included lung and/or bone metastasis. Finally, lung
and/or bone metastasis was also selected as one of the
independent prognostic factor for PFS (adjusted HR 1.5, 95%
CI 1.1-2.1, P = 0.005) (Table S1).
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Subgroup Analysis According to EHS or Regional Node
Metastasis and AFP
The OS and PFS of subgroups according to the presence of
EHS and/or RNI were compared (Table 3). In each subgroup,
patients treated with S-LRTs had longer OS compared to those
treated with S-M (18.0 months vs. 7.8 months in a subgroup
with neither EHS nor RNI and 8.3 months vs. 4.8 months in a
subgroup with EHS and/or RNI; all P < 0.05). In addition,
patients treated with S-LRTs had longer PFS compared to
those treated with S-LRTs in a subgroup with neither EHS nor
RNI (9.6 months vs. 3.2 months, P = 0.027). However, the
therapeutic benefit of LRTs was only marginal in a subgroup
with EHS and/or RNI (4.9 months vs. 2.9 months, P = 0.069).
The OS and PFS of subgroups were also affected by AFP
level (<400 ng/mL vs. ≥400 ng/mL). In the subgroup with low
AFP level (<400 ng/mL), the therapeutic benefit of LRTs to
prolong OS did not reach the statistical significance (P =
0.449). However, in the subgroup with high AFP level (≥400 ng/
mL), the LRTs was effective to improve the OS (3.4 months vs.
8.0 months, P = 0.001). Regarding PFS, similar results were
obtained. Although the S-LRTs could not increase PFS in the
subgroup of low AFP level (<400 ng/mL) (P = 0.225), it
extended PFS significantly in the subgroup of high AFP level
(≥400 ng/mL) (2.0 months vs. 4.2 months, P = 0.012).
Treatment-Related Toxicity
The treatment-related adverse effects of grade 2 or more are
described in Table 4. The most common toxicity related to
sorafenib was hand foot-skin reaction (23.0% in S-M group vs.
23.4% in S-LRTs group), followed by diarrhea (16.4% in S-M
group vs. 15.6% in S-LRTs group). Grade 3 or 4 toxicities were
relatively uncommon and hand foot-skin reaction of grade 3 or
more was found in 8 (4.8%) patients in the S-M group and 2
(3.7%) patients in the S-LRTs group. Except anorexia, the
addition of LRTs to sorafenib did not increase the occurrence
of significant toxicities (all P > 0.05). All adverse events were
manageable and there was no significance difference of the
sorafenib discontinuation due to adverse effects between two
groups.
Table 1. Baseline characters of patients in entire cohort.
Variables  Entire population (n = 290) S-M group (n= 226, 77.9%) S-LRTs group (n = 64, 22.1%) P
Age (years)  56.7 (27.0–85.0) 57.0 (27.0–85.0) 56.0 (28.0–79.0) NS
Male gender  243 (83.8) 188 (83.2) 55 (85.9) NS
Etiology, viral/ non-viral  250 (86.2)/40 (13.8) 190 (84.1)/36 (15.9) 60 (93.8)/4 (6.2) 0.047
ECOG, 0/1~2  84 (29.0)/206 (71.0) 63 (27.9)/163 (72.1) 21 (32.8)/43 (67.2) NS
Child-Pugh class, A/B  208(71.7)/82 (28.3) 161 (71.2)/65 (28.8) 47 (73.4)/17 (26.6) NS
Tumor size (cm)  4.0 (0.7–20.0) 4.0 (1.0–20.0) 4.7 (0.7–16.0) NS
Presence of EHS  182 (62.8) 147 (65.0) 35 (54.7) NS
Presence of lung metastasis  132 (45.5) 109 (48.2) 23 (35.9) 0.081
Presence of bone metastasis  44 (15.2) 39 (17.3) 5 (7.8) 0.063
Presence of distant LN metastasis  26 (9.0) 17 (7.5) 9 (14.1) NS
Presence of RNI  89 (30.7) 66 (29.2) 23 (35.9) NS
Prior history of HCC treatment¶  223 (76.9) 180 (79.6) 43 (67.2) 0.037
 Surgery 17 13 4  
 RFA 2 2 0  
 PEIT 0 0 0  
 TACE 97 71 26  
 TACE with RFA 4 1 3  
 TACE with radiotherapy 9 9 0  
 HAIC with radiotherapy 86 78 8  
 HAIC 5 4 1  
 Radiotherapy 3 2 1  
AFP, ng/mL  110 (0.9–120,000.0) 231.3 (1.1–120,000.0) 160.5 (0.9–83,000.0) NS
PIVKA, AU/L  112 (6.2–75,000.0) 733.0 (6.2–75,000.0) 329.5 (10.0–2,000.0) 0.098
Ln total dosage (mg  10.7 (5.9–13.4) 10.7 (5.9–13.4) 10.9 (8.5–12.8) NS
Abbreviations: S-M, sorafenib monotherapy; S-LRTs, sorafenib combined with loco-regional treatments; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular
carcinoma; EHS, extrahepatic spread; LN, lymph node; RNI, regional nodal involvement; RFA, radiofrequency ablation; PEIT, percutaneous ethanol injection therapy; TACE,
trans-arterial chemoembolization; HAIC, hepatic arterial infusional chemotherapy; AFP, α-fetoprotein; PIVKA, protein induced by vitamin K absence; Ln, natural logarithm;
NS, not significant.
Values are expressed as median (range) or no. (%).
¶ If different anti-cancer treatment modalities were performed repeatedly before enrollment, the latest treatment modality was recorded as the “prior history of HCC
treatment”.
doi: 10.1371/journal.pone.0077240.t001
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Discussion
For advanced-stage disease, the multikinase inhibitor
sorafenib is the new standard treatment with a proven survival
benefit [5,6]. However, since sorafenib predominantly results in
delayed tumor progression by inhibiting tumor cell proliferation
rather than shrinking tumors, most patients treated with
sorafenib alone achieve only stable disease as the best
Figure 1.  Kaplan-Meier analysis of overall survival (A) and progression-free survival (B) in patients.  Data were stratified by
the treatment modalities treated with sorafenib monotherapy (S-M) and sorafenib-based loco-regional treatments (S-LRTs). The
thick line indicates S-LRTs and the thin line S-M. Median OS and PFS are significantly longer in S-LRTs than S-M.
doi: 10.1371/journal.pone.0077240.g001
Table 2. Univariate and multivariate analysis for variables affecting overall and progression-free survival.
Variables Overall survival  Progression-free survival
 Univariate  Multivariate analysis  Univariate  Multivariate analysis
 P  Adjusted HR (95% CI) P  P  Adjusted HR (95% CI) P
S-LRTs (vs. S-M) <0.001  0.5 (0.3–0.8) 0.002  0.002  0.6 (0.4–0.9) 0.025
Age ≥65 (vs. < 65 years) 0.819  - -  0.116  - -
Male (vs. female) 0.809  - -  0.221  - -
Viral etiology (vs. non-viral) 0.428  - -  0.75  - -
ECOG 0 (vs. 1/2) 0.944  - -  0.297  - -
Child-Pugh class B (vs. A) <0.001  1.8 (1.2–2.5) <0.001  0.003  1.4 (1.1–1.9) 0.029
Tumor size≥10 cm (vs. <10 cm) <0.001  1.5 (1.1–2.3) 0.03  0.006  1.6 (1.1–2.4) 0.012
Presence of EHS and/or RNI (vs. no) <0.001  1.7 (1.2–2.4) 0.001  <0.001  1.7 (1.2–2.4) <0.001
Prior history of HCC treatment (vs. no) 0.949  - -  0.992  - -
AFP ≥400 ng/mL (vs. <400 ng/mL) <0.001  1.6 (1.1–2.1) 0.002  <0.001  1.9 (1.4–2.5) <0.001
PIVKA ≥1,000 AU/L (vs. <1,000 AU/L) <0.001  1.2 (0.9–1.6) 0.161  <0.001  1.0 (0.7–1.3) 0.883
Ln total dosage (mg) <0.001  0.5 (0.4–0.6) <0.001  <0.001  0.6 (0.5–0.7) <0.001
Abbreviations: HR, hazard ratio; CI, confidence interval; S-M, sorafenib monotherapy; S-LRTs, sorafenib combined with loco-regional treatments; ECOG, Eastern
Cooperative Oncology Group; EHS, extrahepatic spread; RNI, regional nodal involvement; HCC, hepatocellular carcinoma; AFP, α-fetoprotein; PIVKA, protein induced by
vitamin K absence; Ln, natural logarithm.
doi: 10.1371/journal.pone.0077240.t002
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radiologic response, with a median time to progression of from
2.2 to at most 5.5 months. Thus, new methods beyond
sorafenib treatment are urgently required for HCC. In contrast,
active LRTs including intra-arterial chemotherapy (TACE or
HAIC) and/or external beam radiotherapy induce complete or
partial radiologic response of approximately 30%, even in
advanced HCC [22,24,26,27]. Considering that more than two-
thirds of patients with advanced HCC die of liver failure due to
intrahepatic tumor progression rather than from progression of
extrahepatic metastatic disease, addition of such radical LRTs
targeting the primary tumor might be a reasonable and
effective approach for treating advanced-stage HCC, even in
the presence of MVI, regional lymph node metastasis or EHS.
To obtain pilot data, we investigated the benefits of providing
active LRTs with sorafenib to patients with advanced-stage
HCC.
The OS of the S-M group in our study was relatively shorter
than that of Asia-Pacific trial (5.5 months vs. 6.5 months) [6].
This can be explained in part by the higher proportion of
patients with older age (median 56 years vs. 51 years), poorer
liver function (Child-Pugh class B, 28.3% vs. 2.7%), and more
advanced stage of HCC (BCLC C, 100% vs. 95.3%) in our
study population. Nevertheless, in our study S-LRTs prolonged
the median OS by up to 3 months (8.5 months, P = 0.001),
compared to that of the S-M group (5.5 months). This benefit of
combined treatment was also confirmed through multivariate
analysis after adjusting for other predictors such as Child-Pugh
class, tumor size, EHS and/or RNI, alpha-fetoprotein level, and
cumulative dosage of sorafenib. The beneficial effects of S-
LRTs on OS were similarly observed in subgroups of patients
with neither EHS nor RNI and those with EHS and/or RNI.
Likewise, regarding PFS, S-LRTs prolonged the median PFS
by up to 2.3 months (P = 0.002). Furthermore, when lung
and/or bone metastasis were incorporated into multivariate
analysis instead of EHS and/or RNI, the independent
prognostic values of lung and/or bone metastasis and S-LRT
were also similarly maintained for both OS and PFS.
Interestingly, when tumor burden was high, reflected by high
AFP level (≥400 ng/mL), the effectiveness of S-LRTs became
more prominent in improving OS and PFS (Table 3). These
results support again the rationale that LRTs should be
considered for advanced HCC with high tumor burden. Taken
together, S-LRTs might delay intra-hepatic tumor progression
and by extension, result in preserving the remnant liver function
and ultimately prolonging the OS. The mechanism of action
remains to be further investigated.
Although the promising results of active LRTs warrant further
validation in larger prospective trials, our study had several
strengths. First, the sample size in this study was larger and
the follow-up period was longer than any previous studies
[18-20]. Second, we have suggested how to improve the
treatment responses of sorafenib treatment on the assumption
that active LRTs might delay the hepatic failure due to the
intrahepatic tumor progression. Thus, this study might be
Table 4. Treatment-related adverse effects.
  S-M S-LRTs P
Major adverse effects
of grade 2 or more     
 HFSR 52 (23.0) 15 (23.4) NS
 Diarrhea 37 (16.4) 10 (15.6) NS
 Skin eruption 17 (7.5) 7 (10.9) NS
 Anorexia 10 (4.4) 8 (12.5) 0.034
 Abdominal pain 19 (8.4) 8 (12.5) NS
 Sorafenib discontinuationdue to adverse effects 64 (28.3) 19 (29.7) NS
Abbreviations: S-M, sorafenib monotherapy; S-LRTs, sorafenib combined with
loco-regional treatments; HFSR, hand foot-skin reaction; NS, not significant.
doi: 10.1371/journal.pone.0077240.t004
Table 3. Overall and progression-free survival according to tumor factors in subgroups.
Population  Median OS (95% CI) (months) Hazard Ratio (95% CI) for S-LRTs (vs. S-M) P
  S-M S-LRTs   
Entire cohort  5.5 (4.7–6.2) 8.5 (6.2–10.7) 0.5 (0.4–0.7) 0.001
 Subgroup with neither EHS nor RNI 7.8 (6.2–9.3) 18.0 (3.7–33.2) 0.4 (0.2–0.9) 0.019
 Subgroup with EHS and/or RNI 4.8 (3.7–5.8) 8.3 (5.0–11.5) 0.6 (0.4–0.9) 0.028
 Subgroup with AFP <400 ng/mL 7.8 (6.6–8.9) 8.3 (5.2–11.3) 0.8 (0.5–1.3) 0.449
 Subgroup with AFP ≥400 ng/mL 3.4 (2.5–4.2) 8.0 (0.0–19.0) 0.3 (0.1–0.6) 0.001
Population  Median PFS (95% CI) (months) Hazard Ratio (95% CI) for S-LRTs (vs. S-M) P
  S-M S-LRTs   
Entire cohort  3.0 (2.7–3.2) 5.3 (4.0–6.5) 0.6 (0.4–0.8) 0.002
 Subgroup with neither EHS nor RNI 3.2 (1.8–4.5) 9.6 (3.1–16.0) 0.5 (0.2–0.9) 0.027
 Subgroup with EHS and/or RNI 2.9 (2.5–3.2) 4.9 (4.0–5.7) 0.7 (0.4–1.0) 0.069
 Subgroup with AFP <400 ng/mL 4.0 (2.6–5.3) 6.8 (4.1–9.4) 0.7 (0.4–1.1) 0.225
 Subgroup with AFP ≥400 ng/mL 2.0 (1.6–2.3) 4.2 (2.6–5.7) 0.5 (0.3–0.8) 0.012
Abbreviations: OS, overall survival; PFS, progression-free survival; CI, confidence interval; S-M, sorafenib monotherapy; S-LRTs, sorafenib combined with loco-regional
treatments; EHS, extrahepatic spread; RNI, regional nodal involvement.
doi: 10.1371/journal.pone.0077240.t003
Loco-Regional Treatments in Hepatoma
PLOS ONE | www.plosone.org 6 October 2013 | Volume 8 | Issue 10 | e77240
expected to provide a basic reference for further research on
the addition of LRTs with sorafenib administration. Third, we
performed subgroup analysis according to tumor status in order
to identify who are more likely to benefit from additional LRTs.
The therapeutic benefit for both OS and PFS was greater in the
subgroup with neither EHS nor RNI than in the subgroup with
EHS and/or RNI. However, since additional LRTs are aimed
primarily at controlling the disease progression in the liver, the
therapeutic effect for prolonging PFS is only marginal in a
certain subgroup with EHS and/or RNI where the progression
of EHS or RNI is beyond the effect of additional LRTs.
Strikingly, even in such a subgroup, additional LRTs were
helpful in reducing the events of hepatic failure due to
intrahepatic tumor progression, ultimately leading to
significantly prolonged OS. Therefore, the concurrent use of
active LRTs might be a reasonable approach for treating
advanced HCC.
Notably, among other predictors, the cumulative dosage of
sorafenib, which depends on the daily administration dosage
and duration of treatment, proved to be an independent
prognostic predictor for both OS and PFS. This observation
indicates that sorafenib should be administered as long as
patients tolerate the treatment and further confirms the
importance of sorafenib at the core of HCC therapy. In the
current study the incidence of adverse effects due to sorafenib
treatment were similar to those reported in other investigations
[28-30]. More importantly, the addition of active LRTs did not
increase the overall incidence of adverse events owing to
sorafenib administration. However, physicians should always
exercise caution when combining modalities.
There are several possible explanations for the beneficial
effects of combining sorafenib with other LRTs. Although TACE
induces tumor hypoxia, angiogenic factors such as VEGF
temporarily increase after TACE. Therefore, the enhanced
expression of circulating or tissue VEGF after TACE treatment
could adversely affect the outcome of HCC patients, through
revascularization, tumor progression, and distant metastasis
[31]. From this view point, combining an anti-angiogenic agent
with TACE may provide complementary inhibition of
neovascularization and tumor growth [32,33]. Similarly,
radiation exposure may act as a stressing event, inducing the
compensatory activation of multiple intracellular signaling
pathway mediators, such as phosphoinositide 3-kinase,
mitogen-activated protein kinase (MAPK), c-Jun N-terminal
kinase, and nuclear factor-kappa B [34,35]. In particular, VEGF
levels increased in a time- and dose-dependent manner after
sublethal irradiation of HCC cells, which translated to enhanced
intratumor angiogenesis in vivo [36]. Therefore, sorafenib-
mediated blockage of the Raf/MAPK and vascular endothelial
growth factor receptor pathways might enhance the efficacy of
radiation [37,38].
This study has a few limitations. The first drawback is the
retrospective nature of the work, which could lead to selection
bias in determining the treatment modalities. However, we
consecutively enrolled subjects during the study period and the
baseline characteristics between the two groups were very
similar, differing only in the proportion of HCCs with viral
etiologies and previous history of treatment for HCC. As a
matter of fact, the etiologies for HCC and prior treatment
history did not affect the clinical outcomes. Second, active
LRTs used in this study include heterogeneous modalities such
as TACE, HAIC, external-beam radiotherapy, and their
combinations. Although such LRTs demonstrate comparable
outcomes [15,22,34,39], prospective trials are required to solve
this issue. In addition, treatment regimen decisions were based
not only on medical issues, but also non-medical and/or
economic considerations.
In conclusion, the addition of active LRTs to sorafenib
treatment achieved promising results in unresectable HCC
without significantly increasing treatment-related toxicities.
Further, the therapeutic benefits for OS were maintained
regardless of the presence of EHS. These results now require
validation in another population through prospective trials.
Supporting Information
Table S1.  Univariate and multivariate analysis for
variables including lung and/or bone metastasis to affect
overall and progression-free survival.
(DOC)
Author Contributions
Conceived and designed the experiments: SUK. Analyzed the
data: SL BKK. Wrote the manuscript: SL BKK. Collected the
experiments: SL SC YP. Theory development: SUK KHH.
Helped write and revise the manuscript: JYP DYK SHA CYC
KHH SUK.
References
1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics,
2002. CA Cancer J Clin 55: 74-108. doi:10.3322/canjclin.55.2.74.
PubMed: 15761078.
2. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma.
Lancet 362: 1907-1917. doi:10.1016/S0140-6736(03)14964-1.
PubMed: 14667750.
3. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma.
Hepatology 42: 1208-1236. doi:10.1002/hep.20933. PubMed:
16250051.
4. Lencioni R, Crocetti L (2012) Local-regional treatment of hepatocellular
carcinoma. Radiology 262: 43-58. doi:10.1148/radiol.11110144.
PubMed: 22190656.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E et al. (2008)
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:
378-390. doi:10.1056/NEJMoa0708857. PubMed: 18650514.
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S et al. (2009) Efficacy and
safety of sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: a phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol 10: 25-34. doi:10.1016/
S1470-2045(08)70285-7. PubMed: 19095497.
7. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A et al. (2004) BAY
43-9006 exhibits broad spectrum oral antitumor activity and targets the
RAF/MEK/ERK pathway and receptor tyrosine kinases involved in
tumor progression and angiogenesis. Cancer Res 64: 7099-7109. doi:
10.1158/0008-5472.CAN-04-1443. PubMed: 15466206.
Loco-Regional Treatments in Hepatoma
PLOS ONE | www.plosone.org 7 October 2013 | Volume 8 | Issue 10 | e77240
8. Chang YS, Adnane J, Trail PA, Levy J, Henderson A et al. (2007)
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and
induces tumor apoptosis and hypoxia in RCC xenograft models.
Cancer Chemother Pharmacol 59: 561-574. doi:10.1007/
s00280-006-0393-4. PubMed: 17160391.
9. Kim BK, Kang WJ, Kim JK, Seong J, Park JY et al. (2011) (18) F-
fluorodeoxyglucose uptake on positron emission tomography as a
prognostic predictor in locally advanced hepatocellular carcinoma.
Cancer 117: 4779-4787. doi:10.1002/cncr.26099. PubMed: 21469082.
10. Kim HY, Park JW, Nam BH, Kim HK, Choi JI et al. (2011) Survival of
patients with advanced hepatocellular carcinoma: sorafenib versus
other treatments. J Gastroenterol Hepatol 26: 1612-1618. doi:10.1111/j.
1440-1746.2011.06751.x. PubMed: 21517968.
11. Qu XD, Chen CS, Wang JH, Yan ZP, Chen JM et al. (2012) The
efficacy of TACE combined sorafenib in advanced stages
hepatocellullar carcinoma. BMC Cancer 12: 263. doi:
10.1186/1471-2407-12-263. PubMed: 22721173.
12. Yoon SM, Lim YS, Won HJ, Kim JH, Kim KM et al. (2012) Radiotherapy
plus transarterial chemoembolization for hepatocellular carcinoma
invading the portal vein: long-term patient outcomes. Int J Radiat Oncol
Biol Phys 82: 2004-2011. doi:10.1016/j.ijrobp.2011.03.019. PubMed:
21621346.
13. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R et al. (2008)
Transcatheter arterial chemoembolization (TACE) in hepatocellular
carcinoma (HCC): the role of angiogenesis and invasiveness. Am J
Gastroenterol 103: 914-921. doi:10.1111/j.1572-0241.2007.01712.x.
PubMed: 18177453.
14. Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ et al. (2008) Increased
expression of vascular endothelial growth factor in hepatocellular
carcinoma after transcatheter arterial chemoembolization. Acta Radiol
49: 523-529. doi:10.1080/02841850801958890. PubMed: 18568538.
15. Yoo DJ, Kim KM, Jin YJ, Shim JH, Ko GY et al. (2011) Clinical outcome
of 251 patients with extrahepatic metastasis at initial diagnosis of
hepatocellular carcinoma: does transarterial chemoembolization
improve survival in these patients? J Gastroenterol Hepatol 26:
145-154. doi:10.1111/j.1440-1746.2010.06341.x. PubMed: 21175808.
16. Lee JM, Han KH (2010) Positioning and indication of sorafenib in the
treatment algorithm and real practice setting: Western and eastern
approach--Asian perspective. Oncology 78: 167-171. doi:
10.1159/000315246. PubMed: 20616600.
17. Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevila-Pico C et al. (2011)
The combination of sorafenib with transarterial chemoembolisation for
hepatocellular carcinoma. Aliment Pharmacol Ther 34: 205-213. doi:
10.1111/j.1365-2036.2011.04697.x. PubMed: 21605146.
18. Park JW, Koh YH, Kim HB, Kim HY, An S et al. (2012) Phase II study
of concurrent transarterial chemoembolization and sorafenib in patients
with unresectable hepatocellular carcinoma. J Hepatol 56: 1336-1342.
doi:10.1016/j.jhep.2012.01.006. PubMed: 22314421.
19. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N et al. (2011)
Phase II trial of sorafenib combined with concurrent transarterial
chemoembolization with drug-eluting beads for hepatocellular
carcinoma. J Clin Oncol 29: 3960-3967. doi:10.1200/JCO.
2011.37.1021. PubMed: 21911714.
20. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY et al. (2011) Phase
III study of sorafenib after transarterial chemoembolisation in Japanese
and Korean patients with unresectable hepatocellular carcinoma. Eur J
Cancer 47: 2117-2127. doi:10.1016/j.ejca.2011.05.007. PubMed:
21664811.
21. Liver Korean Cancer Study Group and National Cancer Center (2009)
Practice guidelines for management of hepatocellular carcinoma 2009.
Korean J Hepatol 15: 391-423. doi:10.3350/kjhep.2009.15.3.391.
PubMed: 19783891.
22. Han KH, Seong J, Kim JK, Ahn SH, Lee do Y et al. (2008) Pilot clinical
trial of localized concurrent chemoradiation therapy for locally
advanced hepatocellular carcinoma with portal vein thrombosis. Cancer
113: 995-1003. doi:10.1002/cncr.23684. PubMed: 18615601.
23. Aaltonen T, Adelman J, Akimoto T, Albrow MG, González BA et al.
(2008) Forward-backward asymmetry in top-quark production in
pp[over] collisions at sqrt[s]=1.96 TeV. Phys Rev Lett 101: 202001. doi:
10.1103/PhysRevLett.101.202001. PubMed: 19113329.
24. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW et al. (2007) Repetitive
short-course hepatic arterial infusion chemotherapy with high-dose 5-
fluorouracil and cisplatin in patients with advanced hepatocellular
carcinoma. Cancer 110: 129-137. doi:10.1002/cncr.22759. PubMed:
17508408.
25. Seong J, Lee IJ, Shim SJ, Lim do H, Kim TH et al. (2009) A multicenter
retrospective cohort study of practice patterns and clinical outcome on
radiotherapy for hepatocellular carcinoma in Korea. Liver Int 29:
147-152. doi:10.1111/j.1478-3231.2008.01873.x. PubMed: 18795897.
26. Kim JK, Han KH, Lee JT, Paik YH, Ahn SH et al. (2006) Long-term
clinical outcome of phase IIb clinical trial of percutaneous injection with
holmium-166/chitosan complex (Milican) for the treatment of small
hepatocellular carcinoma. Clin Cancer Res 12: 543-548. doi:
10.1158/1078-0432.CCR-05-1730. PubMed: 16428498.
27. Koom WS, Seong J, Han KH, Lee do Y, Lee JT (2010) Is local
radiotherapy still valuable for patients with multiple intrahepatic
hepatocellular carcinomas? Int J Radiat Oncol Biol Phys 77:
1433-1440. doi:10.1016/j.ijrobp.2009.07.1676. PubMed: 19896779.
28. Lipworth AD, Robert C, Zhu AX (2009) Hand-foot syndrome (hand-foot
skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib
and sunitinib. Oncology 77: 257-271. doi:10.1159/000258880. PubMed:
19923864.
29. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L et al. (2012)
Efficacy and safety of sorafenib in patients with advanced
hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol
57: 821-829. doi:10.1016/j.jhep.2012.06.014. PubMed: 22727733.
30. Di Costanzo GG, Tortora R, Iodice L, Lanza AG, Lampasi F et al.
(2012) Safety and effectiveness of sorafenib in patients with
hepatocellular carcinoma in clinical practice. Dig Liver Dis 44: 788-792.
doi:10.1016/j.dld.2012.04.001. PubMed: 22579445.
31. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X (2004) Expression of plasma
vascular endothelial growth factor in patients with hepatocellular
carcinoma and effect of transcatheter arterial chemoembolization
therapy on plasma vascular endothelial growth factor level. World J
Gastroenterol 10: 2878-2882. PubMed: 15334691.
32. Jiang H, Meng Q, Tan H, Pan S, Sun B et al. (2007) Antiangiogenic
therapy enhances the efficacy of transcatheter arterial embolization for
hepatocellular carcinomas. Int J Cancer 121: 416-424. doi:10.1002/ijc.
22655. PubMed: 17330237.
33. Sieghart W, Pinter M, Reisegger M, Müller C, Ba-Ssalamah A et al.
(2012) Conventional transarterial chemoembolisation in combination
with sorafenib for patients with hepatocellular carcinoma: a pilot study.
Eur Radiol 22: 1214-1223. doi:10.1007/s00330-011-2368-z. PubMed:
22215073.
34. Cheng JC, Chou CH, Kuo ML, Hsieh CY (2006) Radiation-enhanced
hepatocellular carcinoma cell invasion with MMP-9 expression through
PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 25:
7009-7018. doi:10.1038/sj.onc.1209706. PubMed: 16732316.
35. Chung YL, Jian JJ, Cheng SH, Tsai SY, Chuang VP et al. (2006)
Sublethal irradiation induces vascular endothelial growth factor and
promotes growth of hepatoma cells: implications for radiotherapy of
hepatocellular carcinoma. Clin Cancer Res 12: 2706-2715. doi:
10.1158/1078-0432.CCR-05-2721. PubMed: 16675562.
36. Ma BB, Bristow RG, Kim J, Siu LL (2003) Combined-modality treatment
of solid tumors using radiotherapy and molecular targeted agents. J
Clin Oncol 21: 2760-2776. doi:10.1200/JCO.2003.10.044. PubMed:
12860956.
37. Cao C, Albert JM, Geng L, Ivy PS, Sandler A et al. (2006) Vascular
endothelial growth factor tyrosine kinase inhibitor AZD2171 and
fractionated radiotherapy in mouse models of lung cancer. Cancer Res
66: 11409-11415. doi:10.1158/0008-5472.CAN-06-2414. PubMed:
17145887.
38. Kim BK, Park JY, Choi HJ, Kim do Y, Ahn SH et al. (2011) Long-term
clinical outcomes of hepatic arterial infusion chemotherapy with
cisplatin with or without 5-fluorouracil in locally advanced hepatocellular
carcinoma. J Cancer Res Clin Oncol 137: 659-667. doi:10.1007/
s00432-010-0917-5. PubMed: 20552225.
39. Kim BK, Ahn SH, Seong JS, Park JY, Kim do Y et al. (2011) Early
alpha-fetoprotein response as a predictor for clinical outcome after
localized concurrent chemoradiotherapy for advanced hepatocellular
carcinoma. Liver Int 31: 369-376. doi:10.1111/j.
1478-3231.2010.02368.x. PubMed: 21083802.
Loco-Regional Treatments in Hepatoma
PLOS ONE | www.plosone.org 8 October 2013 | Volume 8 | Issue 10 | e77240
